<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; ethical</title>
	<atom:link href="http://www.tapanray.in/tag/ethical/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Access Denied, Ethics Demanded: India’s Pharma Detailing at a Turning Point</title>
		<link>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-influence-a-new-era-of-ethical-medical-detailing-in-india</link>
		<comments>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/#comments</comments>
		<pubDate>Fri, 13 Jun 2025 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[limitations]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[representation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10913</guid>
		<description><![CDATA[June 11, 2025 — The Economic Times reports that a prominent pharmaceutical industry association has urged the Union Health Ministry to reconsider its directive that bars medical representatives (MRs) from physically meeting doctors in central government hospitals. The industry argues that the move &#8230; <a href="http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-influence-a-new-era-of-ethical-medical-detailing-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Closed Doors, Open Channels: India’s Ban on Medical Reps in Govt Hospitals Reshapes Pharma Engagement</title>
		<link>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement</link>
		<comments>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/#comments</comments>
		<pubDate>Fri, 06 Jun 2025 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[email]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Govt]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[India’s Ban MR]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10909</guid>
		<description><![CDATA[The June 3, 2025, directive from the Directorate General of Health Services (DGHS), banning medical representatives (MRs) from meeting doctors in central government hospitals, marks a pivotal policy shift in India&#8217;s evolving healthcare ecosystem. It signals a firm step toward &#8230; <a href="http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/closed-doors-open-channels-indias-ban-on-medical-reps-in-govt-hospitals-reshapes-pharma-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Pharma Business Ethics And Performance Interlinked?</title>
		<link>http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-pharma-business-ethics-and-performance-interlinked</link>
		<comments>http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/#comments</comments>
		<pubDate>Mon, 11 Nov 2019 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expect]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Interlinked]]></category>
		<category><![CDATA[multiplier]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[systemic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9768</guid>
		<description><![CDATA[Way back in the 1960s, many could realize that of upcoming consumer-focused business environment will bring business practices under intense stakeholder scrutiny. This prompted both the business schools, as well as the commercial organizations to bring the concept of ‘business &#8230; <a href="http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-pharma-business-ethics-and-performance-interlinked/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OTC Drugs in India: ‘Where Art Thou?’</title>
		<link>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=otc-drugs-in-india-where-art-thou</link>
		<comments>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/#comments</comments>
		<pubDate>Mon, 02 Sep 2019 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advertisement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[classification]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[juggernaut]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[non-prescription]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[rule]]></category>
		<category><![CDATA[schedule K]]></category>
		<category><![CDATA[self-medication]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US_FDA]]></category>
		<category><![CDATA[Where Art Thou]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9692</guid>
		<description><![CDATA[It is now a widely accepted fact that responsible self-medication plays an important role in health care, facilitating greater access to medicines and reducing overall health care cost. With continued improvement in people&#8217;s education, general knowledge and socioeconomic conditions, self-medication has &#8230; <a href="http://www.tapanray.in/otc-drugs-in-india-where-art-thou/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rebuilding Pharma Image: A Laudable Mindset &#8211; Lacking In Many</title>
		<link>http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rebuilding-pharma-image-a-laudable-mindset-lacking-in-many</link>
		<comments>http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/#comments</comments>
		<pubDate>Mon, 24 Jul 2017 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[Astellas]]></category>
		<category><![CDATA[Berger]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[codes]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[David]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[lacking]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[PMCPA]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[profession]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rebuilding]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Uniform]]></category>
		<category><![CDATA[violations]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8326</guid>
		<description><![CDATA[The fierce debate on ethics and compliance related issues in the pharma marketing practices still reverberates, across the globe. One of its key fallout has been ever-increasing negative consumer perception about this sector, sparing a very few companies, if at &#8230; <a href="http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rebuilding-pharma-image-a-laudable-mindset-lacking-in-many/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ease of Doing Pharma Business in India: A Kaleidoscopic View </title>
		<link>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view</link>
		<comments>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/#comments</comments>
		<pubDate>Mon, 28 Mar 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[doing]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ease]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irration]]></category>
		<category><![CDATA[Kaleidoscope]]></category>
		<category><![CDATA[Kaleidoscopic]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7552</guid>
		<description><![CDATA[Ensuring ease of doing any ethical business activity in India, is a new focus area of the Government and is very rightly so. Creating ease of doing ethical pharma business too, falls under this overall national objective. In this article, &#8230; <a href="http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ease-of-doing-pharma-business-in-india-a-kaleidoscopic-view/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Humongous Pharma Corruption: China Ups The Ante&#8230;and India?</title>
		<link>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=humongous-pharma-corruption-china-ups-the-ante-and-india</link>
		<comments>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/#comments</comments>
		<pubDate>Mon, 23 Sep 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alcon]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[Apco]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[behind]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[biopharmaceuticals]]></category>
		<category><![CDATA[bribers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chases]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conducts]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[crack]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[Gan]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Lee]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[remain]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[Sino]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[Values]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3696</guid>
		<description><![CDATA[In the &#8216;pharma bribery&#8217; related scandal in China, many postulated that the Chinese Government has cracked down selectively on Multinational Corporations (MNCs) to extend unfair business advantages for its local players. Media reports of September 2013 indicate that in all &#8230; <a href="http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New ‘Patient Compensation’ Norms on Clinical Trials in India: Overdue Action, Sharp Reaction and Ethical Issues</title>
		<link>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues</link>
		<comments>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/#comments</comments>
		<pubDate>Mon, 25 Feb 2013 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[controlled]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[GSR]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[negligence]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[norms]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[overdue]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reaction]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1996</guid>
		<description><![CDATA[Responding to the damning stricture made by the Supreme Court on January 3, 2013, the Ministry of Health, as expected, by a gazette notification of January 30, 2013 has made the norms of compensation to patients participating in Clinical Trials &#8230; <a href="http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MCI asks Doctors to Prescribe Medicines in Generic Names</title>
		<link>http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mci-asks-doctors-to-prescribe-drugs-in-generic-names</link>
		<comments>http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/#comments</comments>
		<pubDate>Mon, 28 Jan 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[circular]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[formulations]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Spain]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1459</guid>
		<description><![CDATA[Last week, on January 21, 2013, in a circular addressed to the Dean/Principals of all the Medical Colleges, Director of all the hospitals and Presidents of all the State Medical Councils, the Medical Council of India (MCI) called upon the &#8230; <a href="http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
